Skip to main content
Top
Gepubliceerd in: Quality of Life Research 7/2013

01-09-2013 | Original Paper

Elicitation of health state utilities in soft tissue sarcoma

Auteurs: Sarah L. Shingler, Paul Swinburn, Andrew Lloyd, Jose Diaz, Robert Isbell, Stephanie Manson, Charlotte Benson

Gepubliceerd in: Quality of Life Research | Uitgave 7/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Soft tissue sarcomas (STS) are uncommon tumours with varying histological subtypes. There is a paucity of available data concerning the quality-of-life (QoL) impact of STS which could be used to support economic evaluation of future treatments. This study aimed to elicit societal utility values for health states that depict the impact of STS and its treatment.

Methods

Following the development of eight health state vignettes, a sample of 100 members of the UK general public participated in a valuation exercise to elicit utility values using the time trade-off procedure.

Results

The treatment response state was valued as the least burdensome by participants followed by the prospect of stable disease (mean utility value: 0.736 SD 0.21). Serious adverse events were associated with a range of disutilities from −0.236 for grade III/IV pain to −0.357 for grade III/IV nausea/vomiting. Progressive disease was deemed the least desirable outcome and was associated with a substantial decline in utility (−0.473).

Conclusions

Findings suggest advanced STS are associated with significant burden for individuals. Treatment-related adverse events were seen as debilitating, however, progression represents an enormous challenge to QoL. This illustrates the significant value to individuals of extending the progression free survival period.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Carter, N. J., & Keam, S. J. (2010). Trabectedin a review of its use in soft tissue sarcoma and ovarian cancer. Drugs, 70(3), 355–376.PubMedCrossRef Carter, N. J., & Keam, S. J. (2010). Trabectedin a review of its use in soft tissue sarcoma and ovarian cancer. Drugs, 70(3), 355–376.PubMedCrossRef
2.
go back to reference Vincenzi, B., Frezza, A. M., Santani, D., et al. (2010). New therapies in soft tissue sarcoma. Expert Opinion, 15(2), 237–248. Vincenzi, B., Frezza, A. M., Santani, D., et al. (2010). New therapies in soft tissue sarcoma. Expert Opinion, 15(2), 237–248.
3.
go back to reference Casali, P. G., Jost, L., Sleijfer, S., et al. (2008). Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Supp 2), 89–93. Casali, P. G., Jost, L., Sleijfer, S., et al. (2008). Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Supp 2), 89–93.
4.
go back to reference Hensley, M. L. (2010). Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Current Opinion in Oncology, 22, 356–361.PubMedCrossRef Hensley, M. L. (2010). Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Current Opinion in Oncology, 22, 356–361.PubMedCrossRef
6.
go back to reference Parsons, J. A., & Davis, A. M. (2004). Rehabilitation and quality-of-life issues in patients with extremity soft tissue sarcoma. Current Treatment Options in Oncology, 5, 477–488.PubMedCrossRef Parsons, J. A., & Davis, A. M. (2004). Rehabilitation and quality-of-life issues in patients with extremity soft tissue sarcoma. Current Treatment Options in Oncology, 5, 477–488.PubMedCrossRef
7.
go back to reference Peiper M., Matthaei H., Bölke E., Zurakowski D., Orth K., Heinecke A., et al.(2011) Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors. Wien Klin Wochenschr doi: 10.1007/s00508-011-1592-5. Peiper M., Matthaei H., Bölke E., Zurakowski D., Orth K., Heinecke A., et al.(2011) Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors. Wien Klin Wochenschr doi: 10.​1007/​s00508-011-1592-5.
9.
go back to reference National Institute of Health and Clinical Excellence (NICE). (2008). Guide to the methods of technology appraisal. London: NICE. National Institute of Health and Clinical Excellence (NICE). (2008). Guide to the methods of technology appraisal. London: NICE.
10.
go back to reference Kontodimopoulos, N., Aletras, V. H., Paliouras, D., et al. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health, 12, 1151–1157.PubMedCrossRef Kontodimopoulos, N., Aletras, V. H., Paliouras, D., et al. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health, 12, 1151–1157.PubMedCrossRef
11.
go back to reference Crott R., Briggs A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ;11(4):427–34. Epub 2010 May 16. Crott R., Briggs A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ;11(4):427–34. Epub 2010 May 16.
12.
go back to reference Petrill, J., & Cairns, J. (2008). Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Review on Pharmacoecon Outcomes Research, 8(5), 453–461.CrossRef Petrill, J., & Cairns, J. (2008). Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Review on Pharmacoecon Outcomes Research, 8(5), 453–461.CrossRef
13.
go back to reference Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5, 1–30.PubMedCrossRef Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5, 1–30.PubMedCrossRef
15.
go back to reference Lloyd, A., Nafees, B., Narewska, D. S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer, 95, 683–690.PubMedCrossRef Lloyd, A., Nafees, B., Narewska, D. S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer, 95, 683–690.PubMedCrossRef
16.
go back to reference Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., & Watkins, J. (2008). Health state utilities for non-small cell lung cancer. Health and Quality of Life Outcomes, 6, 84.PubMedCrossRef Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., & Watkins, J. (2008). Health state utilities for non-small cell lung cancer. Health and Quality of Life Outcomes, 6, 84.PubMedCrossRef
17.
go back to reference Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998). Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ, 316, 736.PubMedCrossRef Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998). Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ, 316, 736.PubMedCrossRef
18.
go back to reference Launois, R., Reboul-Marty, J. M., Henry, B., & Bonneterre, J. (1997). A cost/utility analysis of second line chemotherapy in metastatic breast cancer. Pharmaco Economics, 11(5), 495–497.CrossRef Launois, R., Reboul-Marty, J. M., Henry, B., & Bonneterre, J. (1997). A cost/utility analysis of second line chemotherapy in metastatic breast cancer. Pharmaco Economics, 11(5), 495–497.CrossRef
19.
go back to reference Kattan, M. W., Cowen, M. E., & Miles, B. J. (1997). A decision analysis for treatment of clinically localized prostate cancer. Journal of General Internal Medicine, 12(5), 299–305.PubMedCrossRef Kattan, M. W., Cowen, M. E., & Miles, B. J. (1997). A decision analysis for treatment of clinically localized prostate cancer. Journal of General Internal Medicine, 12(5), 299–305.PubMedCrossRef
20.
go back to reference Swinburn, P., Lloyd, A., Nathan, P., Choueiri, T. K., Cella, D., & Neary, M. (2010). Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 26(5), 1091–1096.PubMedCrossRef Swinburn, P., Lloyd, A., Nathan, P., Choueiri, T. K., Cella, D., & Neary, M. (2010). Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 26(5), 1091–1096.PubMedCrossRef
21.
go back to reference Coghill D., et al. (2004) Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Coghill D., et al. (2004) Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP).
22.
go back to reference Lloyd A. (2011). Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations Patient; 4 (4): 247–257. Lloyd A. (2011). Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations Patient; 4 (4): 247–257.
23.
go back to reference Ubel, P. A., Loewenstein, G., & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Quality of Life Research, 12, 599–607.PubMedCrossRef Ubel, P. A., Loewenstein, G., & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Quality of Life Research, 12, 599–607.PubMedCrossRef
24.
go back to reference Kostopoulou, O. (2006). The transient nature of utilities and health preferences. Medical Decision Making, 26, 304–306.PubMedCrossRef Kostopoulou, O. (2006). The transient nature of utilities and health preferences. Medical Decision Making, 26, 304–306.PubMedCrossRef
25.
go back to reference Dolan, P., & Kahneman, D. (2008). Interpretations of utility and their implications for the valuation of health. The Economic Journal, 18, 215–234. Dolan, P., & Kahneman, D. (2008). Interpretations of utility and their implications for the valuation of health. The Economic Journal, 18, 215–234.
26.
go back to reference Blumenschein K., Blomquist G., Johannesson M. et al. Eliciting willingness to pay without bias: Evidence from a field experiment. The Economic Journal; 18: 114–137. Blumenschein K., Blomquist G., Johannesson M. et al. Eliciting willingness to pay without bias: Evidence from a field experiment. The Economic Journal; 18: 114–137.
Metagegevens
Titel
Elicitation of health state utilities in soft tissue sarcoma
Auteurs
Sarah L. Shingler
Paul Swinburn
Andrew Lloyd
Jose Diaz
Robert Isbell
Stephanie Manson
Charlotte Benson
Publicatiedatum
01-09-2013
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 7/2013
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-012-0301-9

Andere artikelen Uitgave 7/2013

Quality of Life Research 7/2013 Naar de uitgave